Debiopharm, Ipsen extend strategic Decapeptyl partnership for another 15 years

This article was originally published here

Having established their collaboration in the 1980s, this extension represents a long-term commitment to patients, offering the benefits of Decapeptyl in the treatment of metastatic and non-metastatic patients

The post Debiopharm, Ipsen extend strategic Decapeptyl partnership for another 15 years appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply